A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

PHASE2CompletedINTERVENTIONAL
Enrollment

713

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Respiratory Tract Infection
Interventions
BIOLOGICAL

RSV Vaccine

RSV vaccine

BIOLOGICAL

Tdap

Tetanus, Diphtheria, and Acellular Pertussis Vaccine

BIOLOGICAL

Placebo

Normal saline solution for injection (0.9% sodium chloride injection)

Trial Locations (16)

30281

Clinical Research Atlanta, Stockbridge

57049

Meridian Clinical Research, LLC, Dakota Dunes

63141

Sundance Clinical Research, St Louis

67207

Alliance for multispecialty research, Wichita

68134

Meridian Clinical Research, Omaha

73112

Lynn Health Science Institute, Oklahoma City

76104

Ventavia Research Group, Fort Worth

77081

Texas Center for Drug Development, Houston

77375

Martin Diagnostic Clinic, Tomball

78229

Clinical Trials of Texas, Inc., San Antonio

78705

Benchmark Research, Austin

84095

J. Lewis Research, Inc / Jordan River Family Medicine, South Jordan

84109

J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City

84121

J. Lewis Research, Inc. / Foothill Family Clinic South, Salt Lake City

96814

East-West Medical Research Institute, Honolulu

02886

Omega Medical Research, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04071158 - A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS | Biotech Hunter | Biotech Hunter